AC Immune backs alpha-synuclein despite recent setbacks
The group’s purchase of Affiris’s Parkinson’s portfolio comes after stumbles from Roche/Prothena and Biogen.
MPS 2021 – Denali disappoints in Hunter syndrome
The group will need longer-term data to justify its huge valuation.
The moral battle lines are drawn in Alzheimer’s
Biogen goes on the offensive against “misinformation” and a media assault, but Roche says patients want clinical benefit, “not imaging”.
After the Aduhelm euphoria, reality bites
The practicalities of actually selling the controversial new Alzheimer’s drug are proving increasingly difficult for Biogen.
Alzheimer’s and Covid-19 developers make hay on the stock markets
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
Why Glaxo should buy Biohaven
And four other potential targets that could make sense for the beleaguered group.
Big pharma leads the way in stock market resurgence
And Lilly was well ahead of the pack, fuelled by Alzheimer’s hopes.
